No-Flush Niacin by NutriCology — Ingredients, Evidence & Safety

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 430mg is 12.3× the Tolerable Upper Intake Level (35mg)

This product received a low safety score because the amount of niacin it contains is more than 12 times higher than the recommended maximum daily limit.

Label Data

1 Capsule(s) Serving Size

75 Servings

Vitamin Product Type

100% Evidence Coverage

Supplement Facts — Evidence Check

Niacin

430 mg (2688% DV)

⚠️ Exceeds Tolerable Upper Intake Level by 12.3× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)

RDA 14mg This product: 430mg UL 35mg

Other Ingredients

Hydroxypropyl Methylcellulose Microcrystalline Cellulose L-Leucine

Label Claims — Verification

❓ Nutrient

❓ All Other

❓ Structure/Function

All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Suggested use As a dietary supplement, 1 capsule two or three times daily with meals, or as directed by a healthcare practitioner.

⚠️ Warnings & Precautions

Do not take large amounts of Niacin (greater than 1.5 grams per day) without first consulting a healthcare practitioner.

🧪 Formulation Notes

Provides inositol hexanicotinate. Taken orally, the Niacin releases slowly, thereby minimizing the likelihood of "niacin flush". Though chemically linked to inositol, the Niacin in this formulation is highly bio-available.

Inositol Hexanicotinate

Hypoallergenic

Additional Information

Keep in a cool, dry place, tightly capped.

NutriCology Innovative Nutrition

Product Details

UPC / SKU 7 13947 50370 0

DSLD Entry Date 2020-09-25

Product Type Vitamin

Form Capsule

Brand NutriCology

DSLD ID 234803

Data Updated 2026-04-11

Research Evidence

241 Research Sources

55 Avg Quality Score

113 Meta Analysis

75 Systematic Review

32 Rct

11 Clinical Trial

3 Other

3 Regulatory Source

1 Cochrane Review

1 Narrative Review

1 Openfda Safety

A Niacin for primary and secondary prevention of cardiovascular events

Meta Analysis The Cochrane database of systematic reviews 2017

PubMed DOI Cochrane

A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases

Meta Analysis BMJ (Clinical research ed.) 2013

PubMed DOI

A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients

Meta Analysis BMJ (Clinical research ed.) 2014

PubMed DOI

A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk

Meta Analysis Nature medicine 2024

PubMed DOI

A Meta-analysis and imputation refines the association of 15q25 with smoking quantity

Meta Analysis Nature genetics 2010

PubMed DOI

A Genome-wide meta-analyses identify multiple loci associated with smoking behavior

Meta Analysis Nature genetics 2010

PubMed DOI

A Antidepressants for smoking cessation

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI

A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne

Meta Analysis The Cochrane database of systematic reviews 2020

PubMed DOI Cochrane

B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis

Meta Analysis JAMA network open 2019

PubMed DOI

B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis

Meta Analysis JAMA 2016

PubMed DOI

View all evidence for Niacin →